



# Antibody-Drug Conjugates: Sharing Best CMC Practices Based On Advanced Scientific Understanding


## Workshop Co-Leaders

Charles Morgan, Denali Therapeutics

Marjorie (Marjie) Shapiro, FDA

Nathan Ihle, Bolt Biotherapeutics

Paresma (Pinky) Patel, FDA



# Helpful White Papers

Control Strategy for Small Molecule Impurities in Antibody-Drug Conjugates.  
Gong, *et al.*, AAPS PharmSciTech 19, 971–977 (2018).

Drug-Linkers in Antibody–Drug Conjugates: Perspective on Current Industry Practices  
Bulger, *et al.*, Organic Process Research & Development 27 (7), 1248-1257 (2023).

Strategies for UF/DF-Based Impurity Removal in the Post-conjugation Purification of Antibody–Drug Conjugates  
Fernandez-Cerezo, *et al.*, Organic Process Research & Development 27 (7), 1258-1268 (2023).

Considerations for Starting Material Designation for Drug-Linkers in Antibody–Drug Conjugates  
Jones, *et al.*, Organic Process Research & Development 27 (7), 1269-1275 (2023).

CMC Regulatory Considerations for Antibody-Drug Conjugates  
Bechtold-Peters, *et al.*, Journal of Pharmaceutical Sciences 112 (2023) 2965–2980.